Minimally Invasive Medicine (00853) fell by more than 14%. As of press release, it was down 14% to HK$5.65, with a turnover of HK$97.901 million.
The Zhitong Finance App learned that Minimally Invasive Healthcare (00853) fell by more than 14%. As of press release, it was down 14% to HK$5.65, with a turnover of HK$97.901 million.
According to the news, Minimally Invasive Healthcare announced its 2023 annual results. The company's revenue was US$951 million, up 15.8% year on year; gross profit of US$532 million, up 6.0% year on year; loss attributable to the company's equity shareholders was US$478 million, up 9.4% year on year; and basic loss per share was 26.19 cents.
Everbright Securities previously reviewed that there were many adverse factors at home and abroad, and the annual results fell short of market expectations. CICC said earlier that the company's revenue growth and loss narrowing in 2023 were lower than market expectations. The bank's judgment was mainly due to the restructuring of the domestic medical industry and problems with the global supply of some products. The company's full-caliber loss reduction in 2023 was limited. Excluding one-time and/or non-cash provisions and loss caliber loss reduction, it was also slightly lower than market expectations. The bank determined that the main reason was that cost reduction and efficiency measures would still take time to gradually implement.